Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) generates a steady flow of news as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. News coverage on this page centers on its internal pipeline, royalty-bearing collaborations, corporate strategy and legal developments.
Investors following ANAB news will see updates on rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial in rheumatoid arthritis and has been evaluated in ulcerative colitis, as well as early-stage programs ANB033 and ANB101. Company announcements describe clinical data readouts, safety and efficacy findings, and decisions to advance or discontinue specific trials, such as the discontinuation of a Phase 2 ulcerative colitis study after not meeting primary and key secondary endpoints at Week 12.
Another key news theme is AnaptysBio’s financial collaborations. Releases detail royalty and milestone expectations from Jemperli (dostarlimab-gxly), the PD-1 antagonist licensed to GSK through Tesaro, and from imsidolimab, the IL-36 receptor antagonist licensed to Vanda Pharmaceuticals. Updates from partners, such as Vanda’s Biologics License Application submission for imsidolimab, also feature prominently because AnaptysBio holds the underlying license.
Corporate and capital allocation developments appear in ANAB news as well, including the company’s intent to separate its biopharma operations from its substantial royalty assets by the end of 2026 and board-authorized stock repurchase plans. Legal and regulatory items, such as AnaptysBio’s litigation with Tesaro and GSK over the Jemperli collaboration and related SEC Form 8-K filings, also contribute to the news flow. This page aggregates these announcements so readers can track how clinical results, royalty assets, strategic separation plans and legal proceedings may shape AnaptysBio’s trajectory over time.
Anaptys (NASDAQ: ANAB) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Completed enrollment for Phase 2b trial of ANB032 in atopic dermatitis, with top-line data expected in December 2024.
2. Accelerated top-line data for Phase 2b trial of rosnilimab in rheumatoid arthritis to Q1 2025.
3. FDA accepted IND for ANB033, with Phase 1 trial initiation anticipated in Q4 2024.
4. Cash and investments of $393.5 million as of June 30, 2024.
5. Q2 2024 net loss of $46.7 million, or $1.71 per share.
The company remains on track to have four immune cell modulators in clinical development by year-end.
AnaptysBio, Inc. (Nasdaq: ANAB) reported financial results for Q1 2024, highlighting progress in Phase 2 trials for ANB032 and rosnilimab, with top-line data expected late 2024 and mid 2025, respectively. IND submissions for ANB033 and ANB101 planned for 2024. Positive Phase 3 trial results for imsidolimab. $50 million revenue from royalty monetization. Cash, cash equivalents, and investments at $370.1 million as of March 31, 2024, with a cash runway through 2026. Collaboration revenue increased to $7.2 million. Research and development expenses up, net loss of $43.9 million.
AnaptysBio, Inc. announces positive top-line results from GEMINI-1 and GEMINI-2 Phase 3 trials for imsidolimab in treating generalized pustular psoriasis (GPP). Patients showed significant improvements in skin clearance with minimal flares. The company plans to out-license imsidolimab in 2024 after demonstrating favorable safety and tolerability profiles.
AnaptysBio, a biotech company, is set to receive $50 million upfront cash payment from Sagard Healthcare as part of an amended agreement. The agreement involves additional royalties for Anaptys Jemperli, with Sagard potentially paying either $600 million by March 31, 2031, or $675 million thereafter. The funds will be used for the development of immune cell modulators in autoimmune and inflammatory diseases, strengthening Anaptys' balance sheet and supporting clinical programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.